What is it about?

Gram-positive bacteria such as Staphylococcus aureus (including MRSA) and enterococci cause many severe infections in hospitals and in the community, and resistance to standard antibiotics keeps growing. In the last years several new drugs have become available: the anti-MRSA cephalosporins ceftobiprole and ceftaroline, the long-acting lipoglycopeptides dalbavancin and oritavancin (which can be given as a single or weekly dose), omadacycline, tedizolid and delafloxacin. In this review, written by microbiologists, pharmacologists and infectious diseases specialists, we describe for each drug its chemical structure, how it works, which bacteria it targets, the results of clinical trials, practical clinical uses, pharmacokinetic and pharmacodynamic properties and the role of therapeutic drug monitoring, with detailed tables.

Featured Image

Why is it important?

With so many new options, choosing the right antibiotic for a resistant Gram-positive infection can be confusing. This comprehensive, practical guide helps clinicians understand the strengths and limitations of each new drug, supporting a more targeted and stratified use that improves outcomes and preserves these valuable molecules.

Perspectives

New antibiotics are only useful if clinicians know how to use them well. I particularly value the multidisciplinary approach of this review, which combines microbiology, pharmacology and clinical experience. Long-acting agents like dalbavancin and oritavancin have truly changed how we manage some patients, allowing earlier discharge.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians, Pharmaceuticals, September 2023, MDPI AG,
DOI: 10.3390/ph16091304.
You can read the full text:

Read

Contributors

The following have contributed to this page